SASP. Because astrocytes have a critical role in the regulation of both synaptic function and cerebral blood flow and are directly exposed to tau at its site of release at the tripartite synapse, we conducted studies to define whether soluble aggregated tau propagates to astrocytes, inducing astrocyte senescence/SASP and neuronal dysfunction/damage. Our studies indicate that tau can be propagated transcellularly to astrocytes, triggering cellular senescence/SASP. Our studies suggest that astrocyte senescence is detrimental to dendritic and synaptic structure and density, suggesting that pathogenic soluble tau-induced astrocyte senescence may contribute to synaptic dysfunction and loss in AD. Drugs that eliminate senescent cells are FDA-approved and antibody-based approaches to remove tau from brain are already in clinical trials. Our studies suggest that these interventions could be effective in the treatment of AD and other tauopathies. The cytokine family type I interferon (IFN) is a major innate immune mediator extensively studied in the peripheral immune responses but largely under-investigated in AD. Previously, we established that innate immune cells readily produce IFN in response to amyloid fibrils containing nucleic acids as cofactor. Here, we investigated whether IFN pathway is associated with amyloidosis in AD brain and contributes to neuroinflammation. By systemically characterizing neuroinflammation in multiple murine AD models, we established a comprehensive core AD neuroinflammation profile that includes several key proinflammatory cytokine families, among which IFN pathway is consistently activated. When hippocampal slice culture was stimulated with different forms of amyloid fibrils, nucleic acid-containing amyloid fibrils, but not heparin-containing fibrils, potently activated IFN pathway and triggered comprehensive neuroinflammation. In addition, stereotaxic administration of IFNβ induced an immune response in the brain of wild type mice analogous to the core neuroinflammatory profile associated with Aβ pathology; whereas selective IFN receptor blockade significantly blunted the ongoing microgliosis in AD models in vivo. Furthermore, IFN promoted microglia-mediated synapse uptake from neurons, which depended on the induction of complement C3, and blockade of IFN signaling significantly abolished the pathogenic synapse loss in AD brain. Consistent with the findings in mice, we found that genes stimulated by IFN were grossly upregulated in human AD brains. Therefore, type I interferon constitutes a major pathway within the neuroinflammatory network of AD and may represent a molecular target to restrain the pathogenic inflammatory responses. Postoperative delirium complicates 15-50% of major surgery in older adults, resulting in poor patient outcomes and increased healthcare costs. Basic mechanisms of delirium are largely unknown. In this study we implemented a protocol that uses high-throughput metabolomics to explore potential biological mechanisms of delirium. We profiled the plasma metabolome of 10 delirium cases and 10 matched controls from the SAGES cohort of older adults without dementia undergoing major non-cardiac surgery. We used targeted mass spectrometry to measure 302 metabolites (features) preoperatively (PREOP) and on postoperative day 2 (POD2). Metabolomics studies are challenged by inherent technical variability and signal noise. With a small sample and a large feature count, signal noise diminishes statistical power and masks true biological signals. To address these challenges, we implemented quality control sample-based signal correction and normalization to internal standards (ISs). ISs were screened from a pool of 6 potential candidates, resulting in the removal of 3 that failed to perform well, while 3 were retained for our experiments. ISs also enabled successful concatenation of experiments run at different times. Prior to implementing quality control samples and customized ISs, no metabolites were identified as differentially expressed. After implementation, we identified one metabolite that was significantly differentially expressed at PREOP and 17 metabolites that were significantly differentially expressed at POD2 between delirium and controls (BH-corrected p-value < 0.05). In conclusion, integration of quality controls and normalization to internal standards enabled us to detect metabolites associated with postoperative delirium. Such methods should be considered for future metabolomics studies.
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